Related Experiment Video
Updated: Aug 1, 2026

Operant Procedures for Assessing Behavioral Flexibility in Rats
Published on: February 15, 2015
Phase I Stark II regulations provide some flexibility
1Brown & Bain, PA, Tucson, Arizona, USA. chase@brownbain.com
Abstract:
The Centers for Medicare and Medicaid Services (CMS--formerly HCFA) issued Phase I regulations of Stark II in January 2001. The Stark II final rule prohibits physicians from referring Medicare patients for designated health services (DHS) to entities with which the physicians or their immediate family members have a financial relationship. A financial relationship can be either an ownership interest or a compensation arrangement, and can be direct or indirect. The law provides a variety of sanctions, including denial or refund of payment and civil penalties. The final rule generally permits physicians to make referrals to entities with which they have a compensation relationship, as long as the compensation paid to the physician is no more than would be paid to someone who provided the same services but was not in a position to generate business for the entity. The final rule is substantially different from the January 1998 proposed rule. As a result, physicians who refer patients to entities for DHS need to ensure that the referrals do not trigger Stark II prohibitions. To avoid unknowingly violating the law, healthcare providers need to understand what constitutes an entity, how CMS views referrals, and what is and is not a DHS.
Related Concept Videos
Drug Regulation
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Clinically Relevant Drug Product Specifications: Methods of Establishment
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Dosage Regimen: Individualization
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

